News
- Author:
- Liam Davenport
Publish date: October 23, 2023
Dr. Tan noted, the AtTEnd data "continue to validate practice-changing therapy for dMMR endometrial cancer patients."
News
- Author:
- Liam Davenport
Publish date: October 23, 2023
Further analysis may allow the prediction of “relevant changes throughout the course of multiple sclerosis.”
News
- Author:
- Liam Davenport
Publish date: October 20, 2023
About one-third of patients with esophageal cancer who have a compete response to neoadjuvant chemoradiotherapy may be able to avoid surgery. Howev...
News
- Author:
- Liam Davenport
Publish date: October 18, 2023
Each sensor collects a sample every second, resulting in highly detailed and granular data.
News
- Author:
- Liam Davenport
Publish date: October 18, 2023
Weight loss “was associated with improved mobility, reduced fatigability, and improved physical quality of life.”
News
- Author:
- Liam Davenport
Publish date: October 13, 2023
Deep learning–based methods are “useful” in screening for potential interactions both between drugs and with foods.
News
- Author:
- Liam Davenport
Publish date: October 13, 2023
Lower rates of relapse were seen in older patients taking ocrelizumab, but the risk for relapse in this age group is low.
News
- Author:
- Liam Davenport
Publish date: October 12, 2023
“We’ve always known that there was a problem, but there haven’t been high-quality epidemiological studies like this that allowed us to say what the...
News
- Author:
- Liam Davenport
Publish date: October 12, 2023
“These patients are not resistant, they just have resistance to monoaminergic drugs.”
News
- Author:
- Liam Davenport
Publish date: October 11, 2023
Medication “generally had worse impact on body weight, heart rate variability, and blood pressure, whereas running therapy led to improved effect o...
News
- Author:
- Liam Davenport
Publish date: September 21, 2023
People who exercised in the morning had a lower body mass index than those who exercised at other times, even though they were more sedentary.
News
- Author:
- Liam Davenport
Publish date: September 18, 2023
Without “incontrovertible evidence” that immunotherapy should stop at 2 years, “many, many, many patients and clinicians are going to favor continu...
News
- Author:
- Liam Davenport
Publish date: September 14, 2023
Lung cancers, particularly those with T1 disease, could be reclassified into a different overall stage if proposed adaptations to the N and M categ...
News
- Author:
- Liam Davenport
Publish date: September 14, 2023
Combining osimertinib with chemotherapy improved progression-free survival in EGFR-mutated non–small cell lung cancer, new interim data show, but e...
News
- Author:
- Liam Davenport
Publish date: September 12, 2023
A phase 2 trial found that almost 30% of patients receiving antibody-drug conjugate patritumab deruxtecan achieved an objective response, and patie...
